217 related articles for article (PubMed ID: 10849529)
21. The clinical significance of tumor cells in bone marrow or apheresis product and the efficacy of CD34+ selection and high-dose chemotherapy in patients with Stage III breast cancer.
Arpaci F; Safali M; Ozet A; Ural AU; Cetin T; Ozturk M; Ataergin S; Kuzhan O; Komurcu S; Ozturk B; Acikel C
J Clin Apher; 2009; 24(5):197-204. PubMed ID: 19816961
[TBL] [Abstract][Full Text] [Related]
22. High-dose chemotherapy and stem cell transplantation for patients with stage IV breast cancer without clinically evident disease: correlation of CD34+ selection to clinical outcome.
Ahmed T; Kancherla R; Qureshi Z; Mittelman A; Seiter K; Mannancheril A; Puccio C; Chun HG; Bar M; Lipshutz M; Ali MF; Goldberg R; Preti R; Lake D; Durrani H; Farley T
Bone Marrow Transplant; 2000 May; 25(10):1041-5. PubMed ID: 10828863
[TBL] [Abstract][Full Text] [Related]
23. Elimination of bcl-2-IgH-positive follicular lymphoma cells from blood transplants with high recovery of hematopoietic progenitors by the miltenyi CD34+ cell sorting system.
Di Nicola M; Siena S; Corradini P; Bregni M; Milanesi M; Magni M; Ruffini PA; Ravagnani F; Tarella C; Gianni AM
Bone Marrow Transplant; 1996 Dec; 18(6):1117-21. PubMed ID: 8971381
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of the immunocytochemical detection of contaminating tumor cells (CTC) in apheresis products of patients with high-risk breast cancer treated with high-dose chemotherapy and stem cell transplantation.
Solano C; Badia B; Lluch A; Marugan I; Benet I; Arbona C; Prosper F; García-Conde J
Bone Marrow Transplant; 2001 Feb; 27(3):287-93. PubMed ID: 11277176
[TBL] [Abstract][Full Text] [Related]
25. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
Steingrimsdottir H; Gruber A; Björkholm M; Svensson A; Hansson M
Haematologica; 2000 Aug; 85(8):832-8. PubMed ID: 10942930
[TBL] [Abstract][Full Text] [Related]
26. Hematopoietic recovery of ex vivo perfusion culture expanded bone marrow and unexpanded peripheral blood progenitors after myeloablative chemotherapy.
Engelhardt M; Douville J; Behringer D; Jähne A; Smith A; Henschler R; Lange W
Bone Marrow Transplant; 2001 Feb; 27(3):249-59. PubMed ID: 11277172
[TBL] [Abstract][Full Text] [Related]
27. Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT).
Ergene U; Cağirgan S; Pehlivan M; Yilmaz M; Tombuloğlu M
Transfus Apher Sci; 2007 Feb; 36(1):23-9. PubMed ID: 17292672
[TBL] [Abstract][Full Text] [Related]
28. Clinical impact of ex vivo differentiated myeloid precursors after high-dose chemotherapy and peripheral blood progenitor cell rescue.
Zimmerman TM; Lee WJ; Bender JG; Schilling M; Smith SL; Van Epps DE; Williams SF
Bone Marrow Transplant; 2000 Sep; 26(5):505-10. PubMed ID: 11019839
[TBL] [Abstract][Full Text] [Related]
29. Tumor cell depletion of peripheral blood progenitor cells using positive and positive/negative selection in metastatic breast cancer.
Preti RA; Lazarus HM; Winter J; Stadtmauer EA; Nadasi S; McMannis J; Karandish S; Jennis A; Goldberg SL; Pecora AL
Cytotherapy; 2001; 3(2):85-95. PubMed ID: 12028831
[TBL] [Abstract][Full Text] [Related]
30. Occult tumor cells detected in autologous blood stem cell harvests have no impact on 5 year outcomes for breast cancer patients with 4-9 positive nodes treated with adjuvant high-dose therapy and stem cell transplantation.
Reed E; Kessinger A; Murphy B; Tarantolo S; Traystman M; Sharp JG
Bone Marrow Transplant; 2003 Apr; 31(7):571-4. PubMed ID: 12692623
[TBL] [Abstract][Full Text] [Related]
31. [CD34-positive cell selection using an Isolex 300 system in patients with solid tumors and its application for autologous peripheral blood stem cell transplantation].
Kaneko H; Kimura T; Tsuda S; Ohkawara Y; Abe T; Sonoda Y
Rinsho Ketsueki; 1998 Sep; 39(9):652-7. PubMed ID: 9796398
[TBL] [Abstract][Full Text] [Related]
32. Autografting with peripheral blood CD34-positive cells following high-dose chemotherapy against breast cancer.
Okumura A; Tokuda Y; Ohta M; Suzuki Y; Saito Y; Kuge S; Kubota M; Makuuchi H; Tajima T; Nakamura Y; Hotta T
Tokai J Exp Clin Med; 1999 Dec; 24(4-6):141-6. PubMed ID: 10819494
[TBL] [Abstract][Full Text] [Related]
33. Comparison of two different methods for CD34+ selection and T cell depletion in peripheral blood stem cell grafts--our experiences with CellPro, E rosetting and CliniMACS technique.
Poloucková A; Vodvárková A; Kobylka P; Hrubá A; Gasová Z; Marinov I; Fales I; Sedlácek P; Kozák T; Starý J
Neoplasma; 2001; 48(5):374-81. PubMed ID: 11845982
[TBL] [Abstract][Full Text] [Related]
34. The CD34+90+ cell dose does not predict early engraftment of autologous blood stem cells as well as the total CD34+ cell dose.
Stewart DA; Guo D; Luider J; Auer I; Klassen J; Morris D; Chaudhry A; Brown C; Russell JA; Gluck S
Bone Marrow Transplant; 2000 Feb; 25(4):435-40. PubMed ID: 10723588
[TBL] [Abstract][Full Text] [Related]
35. Autologous bone marrow support and bone disease in metastatic breast cancer.
Nabholtz JM; al-Tweigeri T; Jacquelin N; Venner PM
Can J Oncol; 1995 Jul; 5(2):369-75. PubMed ID: 8853509
[TBL] [Abstract][Full Text] [Related]
36. A multicenter randomized clinical trial evaluating interleukin-2 activated hematopoietic stem cell transplantation and post-transplant IL-2 for high risk breast cancer patients.
Isaacs C; Slack R; Gehan E; Ballen K; Boccia R; Areman E; Kramer R; Hayes DF; Herscowitz H; Lippman M
Breast Cancer Res Treat; 2005 Sep; 93(2):125-34. PubMed ID: 16187232
[TBL] [Abstract][Full Text] [Related]
37. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma.
Fruehauf S; Klaus J; Huesing J; Veldwijk MR; Buss EC; Topaly J; Seeger T; Zeller LW; Moehler T; Ho AD; Goldschmidt H
Bone Marrow Transplant; 2007 Jun; 39(12):743-50. PubMed ID: 17450182
[TBL] [Abstract][Full Text] [Related]
38. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.
Tarella C; Di Nicola M; Caracciolo D; Zallio F; Cuttica A; Omedè P; Bondesan P; Magni M; Matteucci P; Gallamini A; Pileri A; Gianni AM
Bone Marrow Transplant; 2002 Dec; 30(11):725-32. PubMed ID: 12439694
[TBL] [Abstract][Full Text] [Related]
39. Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation.
Allan DS; Keeney M; Howson-Jan K; Popma J; Weir K; Bhatia M; Sutherland DR; Chin-Yee IH
Bone Marrow Transplant; 2002 Jun; 29(12):967-72. PubMed ID: 12098064
[TBL] [Abstract][Full Text] [Related]
40. Tumor cell contamination of peripheral blood stem cell transplants and bone marrow in high-risk breast cancer patients.
Schulze R; Schulze M; Wischnik A; Ehnle S; Doukas K; Behr W; Ehret W; Schlimok G
Bone Marrow Transplant; 1997 Jun; 19(12):1223-8. PubMed ID: 9208116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
